Policy paper urges nonproprietary names for biologic, biosimilar drugs

10/21/2013 | Drug Store News

Biologic drugs and their biosimilar counterparts should share a common, generic name, the Generic Pharmaceutical Association and a policy paper by Hospira's chief scientific officer say. Makers of brand-name drugs say that biosimilars are made from different cell lines than branded biologic drugs and should have different names, but advocates of using common names say biosimilars have the same effects as reference products and differences are not clinically significant.

View Full Article in:

Drug Store News